EMD Serono Research & Development Institute, Inc. clinical trials

Acquired by Merck KGaA, Darmstadt, Germany, Jan 5, 2007 · source ↗

The registry lists 87 studies whose lead sponsor is EMD Serono Research & Development Institute, Inc.. 8 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 87. List all 87 → · All Merck KGaA, Darmstadt, Germany studies →

• Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsRecruitingNCT07360314Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)RecruitingNCT07549412Phase 3

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Anti-GD2 ADC M3554 in Advanced Solid TumorsRecruitingNCT06641908Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid TumorsRecruitingNCT07166601Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic DiseaseRecruitingNCT07332481Phase 3

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)RecruitingNCT07355218Phase 3

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Met Non Small Cell Cancer Registry (MOMENT)RecruitingNCT05376891

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Long-Term Extension (LTE) Study Of Enpatoran In Cutaneous Manifestations Of Lupus With Or Without Systemic Disease [Elowen-LTE]Not yet recruitingNCT07840287Phase 3

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)Active, not recruitingNCT06710132Phase 1/2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)Active, not recruitingNCT05327530Phase 2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Avelumab Program Rollover StudyActive, not recruitingNCT03815643Phase 3

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)CompletedNCT06433219Phase 2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)CompletedNCT05882734Phase 1/2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)CompletedNCT05396833Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Study of M5049 in DM and PM Participants (NEPTUNIA)TerminatedNCT05650567Phase 2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)Active, not recruitingNCT06421935Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)CompletedNCT03940703Phase 2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)Active, not recruitingNCT04170153Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)Active, not recruitingNCT05464030Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS TumorsTerminatedNCT05081180Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)Active, not recruitingNCT02864992Phase 2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• First in Human Study of M6223CompletedNCT04457778Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• First in Human Study of M1069 in Advanced Solid TumorsTerminatedNCT05198349Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male ParticipantsCompletedNCT07097259Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)TerminatedNCT05386550Phase 3

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Bintrafusp Alfa Program Rollover StudyCompletedNCT05061823Phase 3

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)CompletedNCT03933202

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)TerminatedNCT06509906Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)CompletedNCT05162586Phase 2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)TerminatedNCT04459715Phase 3

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)TerminatedNCT06056310Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)WithdrawnNCT06719973Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple SclerosisTerminatedNCT02975349Phase 2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)CompletedNCT03933215

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Study of Avelumab-M3814 CombinationsCompletedNCT03724890Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT03631706Phase 3

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)CompletedNCT04882917Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Avelumab in First-line NSCLC (JAVELIN Lung 100)CompletedNCT02576574Phase 3

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With RadiotherapyCompletedNCT02516813Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)WithdrawnNCT06424717Phase 2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)CompletedNCT04768296Phase 2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)TerminatedNCT02994953Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• The MS-LINK™ Outcomes StudyCompletedNCT04735406

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Tepotinib Hepatic Impairment TrialCompletedNCT03546608Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Phase I/II Study of Avelumab in Pediatric Cancer ParticipantsTerminatedNCT03451825Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Next-Gen MS: Feed-forward PRO Data for MS ResearchTerminatedNCT04907305

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• MSB0011359C (M7824) in Metastatic or Locally Advanced Solid TumorsCompletedNCT02517398Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)CompletedNCT02155647Phase 2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)CompletedNCT04551950Phase 1

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany

• M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)TerminatedNCT03840902Phase 2

  Sponsor listed in the registry: EMD Serono Research & Development Institute, Inc. · First submitted after EMD Serono Research & Development Institute, Inc. became part of Merck KGaA, Darmstadt, Germany